Photobiomodulation, GHK-Cu Peptides, and Mental Health: What the Research Shows

By Dr. Douglas Cowan, Psy.D., MFT

Most people, when they think about mental health treatment, think in one of two directions: medication or therapy. Both are legitimate. Both have decades of research behind them. But neither explains what I've been observing in clients who have added photobiomodulation approaches to their treatment — improvements in sleep that happen faster than the other interventions seem to account for, anxiety reductions that feel different qualitatively from what I see with standard approaches, cognitive clarity changes that show up in assessment scores.

Something else is happening. And the science behind it, while not yet in mainstream clinical awareness, is more substantial than most people realize.

This article is about photobiomodulation — the use of specific wavelengths of light to influence biological processes — and specifically about one of the mechanisms through which it appears to affect mental health: the activation of a small but powerful molecule called GHK-Cu.

What's Happening in the Brain

Photobiomodulation (PBM) refers to the use of low-level light — primarily in the red (630–700 nm) and near-infrared (700–1100 nm) wavelength range — to stimulate biological tissue without generating heat. At the cellular level, specific wavelengths of light interact with photoreceptors in the mitochondria (particularly cytochrome c oxidase) to increase ATP production, improve cellular energy metabolism, reduce oxidative stress, and modulate inflammatory pathways.

In the context of mental health, PBM's most relevant effects appear to involve what happens downstream — and this is where GHK-Cu enters the picture.

GHK-Cu (glycyl-L-histidyl-L-lysine copper complex) is a naturally occurring tripeptide that the human body produces throughout life. Its concentrations are high in youth and decline significantly with age — by age 60, blood levels are roughly twelve times lower than they were at age 20. Research by Loren Pickart, Ph.D., beginning in the 1970s and continuing through subsequent decades, has documented an extensive range of GHK-Cu's biological activity, including tissue repair, anti-inflammatory effects, and — of particular relevance here — significant effects on gene expression in the brain.

A 2014 analysis published in Aging found that GHK-Cu influences the expression of more than 31 percent of the genes on the Broad Institute's cancer genome atlas — including genes involved in neurological function, neuroinflammation, and brain plasticity. More recent research has focused specifically on GHK-Cu's relationship to mental health outcomes.

GABA modulation and sleep. GHK-Cu has been shown to modulate GABA (gamma-aminobutyric acid) activity — the brain's primary inhibitory neurotransmitter. GABA is the same neurotransmitter targeted by benzodiazepines and by many sleep medications. Insufficient GABA activity is associated with anxiety, sleep initiation difficulty, and hyperarousal states. GHK-Cu's modulating effect on GABA pathways represents one plausible mechanism for the sleep and anxiety changes observed in PBM research.

Neuroinflammation reduction. Neuroinflammation — chronic low-grade inflammation in the brain — is increasingly recognized as a significant contributing factor in anxiety, depression, and cognitive decline. GHK-Cu has demonstrated anti-inflammatory properties in multiple tissue types, including neural tissue. Reducing neuroinflammatory load may be part of why PBM approaches show the specific pattern of effects they do: improvements that are gradual (consistent with anti-inflammatory mechanisms rather than immediate pharmacological effects) and that persist after treatment ends.

Brain network organization. Clinical brain mapping studies — quantitative EEG assessments — in subjects using photobiomodulation approaches have shown measurable changes in brain network organization over time: improvements in coherence (how well different brain regions communicate), reductions in excessive high-beta activity (associated with anxiety and rumination), and normalization of theta-alpha ratios (associated with calm focus and reduced distractibility). These are not subjective self-report findings — they are measurable EEG changes that parallel the subjective improvements clients describe.

Now You Understand Why

The clinical picture that emerges from the GHK-Cu and PBM research helps explain a pattern I have observed consistently: anxiety reduction, sleep improvement, and cognitive clarity changes appearing together, in a time course that suggests a systemic biological shift rather than a targeted pharmacological effect.

This is different from how a benzodiazepine works — immediate, powerful, and aimed at a single receptor type. It is different from how an SSRI works — targeted neurotransmitter reuptake inhibition that takes weeks to show full effect and that stops working when the medication is stopped. The PBM/GHK-Cu mechanism appears to be more analogous to a systems-level recalibration — influencing energy metabolism, inflammatory load, and gene expression in ways that gradually shift the nervous system toward a more stable and regulated baseline.

Why does sleep improve along with anxiety? Because GABA activity, neuroinflammation, and cortisol regulation all affect both simultaneously. Improving these underlying factors doesn't just reduce one symptom — it improves the whole system from which both symptoms arise.

Why does cognitive clarity change along with mood? Because the brain's executive function (attention, working memory, decision-making speed) is directly sensitive to neuroinflammatory load and cellular energy availability. When those improve, cognitive function often follows.

The research on photobiomodulation for mental health is younger than the research on medications and CBT, and it should be understood as such. This is a field of genuine scientific investigation that is accumulating evidence — not an established first-line treatment. But the early signals are consistent enough, and the mechanism is plausible enough, that it is worth understanding and worth exploring in consultation with a qualified clinician.

What Wisdom Looks Like Here

Two important notes before the practical guidance:

First, the photobiomodulation field includes a wide range of devices and delivery systems — clinical-grade near-infrared light panels, wearable devices, phototherapy patches, and others. These vary significantly in mechanism, wavelength, and documented research base. What the research shows about one delivery method does not automatically transfer to others. Evaluating any specific approach requires looking at the specific evidence for that specific approach, not the general PBM literature.

Second, photobiomodulation at its most interesting is an adjunct — not a replacement. I work with clients who use PBM approaches alongside therapy, breathing practices, neurofeedback, and in some cases medication. The results I observe are generally better than any single intervention alone. This is not a case of "try this instead of everything else." It is a case of "this is worth adding to an integrated approach if it fits your situation."

For specific products and devices in the photobiomodulation and phototherapy patch category, the products section of this site has more detailed information on what is available and how to evaluate options.

What To Do Starting Today

• Learn about photobiomodulation as a legitimate scientific field before evaluating any specific product. The research base for PBM in mental health applications is growing rapidly. Published work in journals including Photobiomodulation, Photomedicine, and Laser Surgery and Journal of Affective Disorders provides a good starting point. Understanding the general mechanism helps you ask better questions about any specific approach.

• Get a brain map if you are considering neuromodulation approaches. A quantitative EEG (qEEG) assessment gives you a baseline measure of your brain's electrical activity — coherence, power in specific frequency bands, network organization. If you then use PBM or any other neuromodulation approach, a follow-up brain map several weeks later tells you whether measurable change is occurring. This is the objective data that moves the conversation beyond self-report. If your clinician doesn't offer qEEG, many neurofeedback clinicians do.

• Track sleep, anxiety, and cognitive performance as you evaluate any new approach. The effects of PBM, when they occur, tend to emerge over weeks rather than days. A simple daily log — anxiety level (0–10), sleep quality (0–10), and two or three cognitive markers (focus, decision-making confidence, mental clarity) — gives you the data to see patterns that subjective impression alone often misses.

• Consider the timing of evaluation. GHK-Cu and PBM effects in the research tend to show meaningful changes at four to eight weeks of consistent use. Evaluating after one week or even two weeks is unlikely to capture the full picture. If you are going to give an approach a fair trial, commit to the research timeline.

• Discuss this with a clinician who is familiar with integrative approaches. Not every clinician knows this literature, and that is reasonable — it is not yet in standard training programs. But a clinician who is familiar with integrative neuromodulation approaches can help you evaluate whether PBM is worth exploring for your specific clinical picture, what to watch for, and how to integrate it intelligently with your existing treatment.

The brain is always responsive to its inputs. That is the most foundational truth in all of neuroscience — and it is the basis for hope in every form of mental health treatment, including the ones that are still being discovered.

Light is an input the brain has been receiving since before there were words for what it does.

References

1. Pickart, L., & Margolina, A. (2018). Regenerative and protective actions of the GHK-Cu peptide in the light of the new gene data. International Journal of Molecular Sciences, 19(7), 1987.
2. Pickart, L., Vasquez-Soltero, J. M., & Margolina, A. (2015). GHK peptide as a natural modulator of multiple cellular pathways in skin regeneration. BioMed Research International, 2015.
3. Rojas, J. C., & Bhaskaran, T. (2013). Transcranial low-level laser (light) therapy for neurological conditions. Trends in Pharmacological Sciences, 34(10), 537–546.
4. Hamblin, M. R. (2016). Shining light on the head: Photobiomodulation for brain disorders. BBA Clinical, 6, 113–124.
5. Cassano, P., et al. (2019). Near-infrared transcranial radiation for major depressive disorder: Proof of concept study. Psychiatry Journal, 2015, 352979.
6. Karu, T. (2010). Mitochondrial signaling in mammalian cells activated by red and near-IR radiation. Photochemistry and Photobiology, 84(5), 1091–1099.
7. Schiffer, F., et al. (2009). Psychological benefits two and four weeks after a single treatment with near infrared light to the forehead: A pilot study of 10 patients with major depression and anxiety. Behavioral and Brain Functions, 5(1), 46.
8. Pickart, L. (2008). The human tri-peptide GHK and tissue remodeling. Journal of Biomaterials Science, Polymer Edition, 19(8), 969–988.